BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Thursday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect BioCryst Pharmaceuticals to post earnings of $0.06 per share and revenue of $151.32 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

BioCryst Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ:BCRX opened at $7.61 on Wednesday. The firm has a fifty day simple moving average of $7.09 and a two-hundred day simple moving average of $7.39. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.31. The stock has a market capitalization of $1.60 billion, a P/E ratio of -152.20 and a beta of 0.83.

Insider Buying and Selling

In related news, insider Alane P. Barnes sold 91,004 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.10, for a total transaction of $646,128.40. Following the completion of the sale, the insider owned 416,152 shares in the company, valued at $2,954,679.20. This trade represents a 17.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 183,453 shares of company stock valued at $1,330,965. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after buying an additional 1,458 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after acquiring an additional 8,517 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in BioCryst Pharmaceuticals by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after acquiring an additional 640,704 shares during the period. Caxton Associates LLP purchased a new stake in BioCryst Pharmaceuticals in the first quarter worth about $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after acquiring an additional 47,355 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, December 29th. Needham & Company LLC lowered their price objective on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Citizens Jmp dropped their target price on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, November 5th. Zacks Research lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Barclays dropped their price objective on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 4th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $19.64.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.